ClinicalTrials.gg
RecruitingNCT07633444TVNS-PAINUpdated Jun 10, 2026

Transauricular Vagus Nerve Stimulation Frequencies for Postoperative Pain

An interventional study of Transauricular Vagus Nerve Stimulation (tVNS) and Sham Transauricular Vagus Nerve Stimulation (sham tVNS) in Postoperative Pain, Postoperative Nausea and Vomiting (PONV) and Opioid Consumption, Postoperative, sponsored by Federal University of Bahia. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Federal University of Bahia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Pain, Postoperative with a site in Brazil — 8 open to participants now, 8 under way, 1 of them phase 3. Pain, Postoperative · Brazil.

Planned enrollment
7th of 53
174 · median 70
Started
2026
with 3 others
No phase
21 of 56
6 open now
Registered
53rd of 56
by date

Among the 56 studies in Pain, Postoperative with a site in Brazil, this one is the 7th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2026, is one of 21 with no phase, and was the 53rd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 56 studies in Pain, Postoperative with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Pain, Postoperative with a site in Brazil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether different frequencies of transauricular vagus nerve stimulation (tVNS) can reduce postoperative pain and opioid consumption in adults undergoing abdominal or urologic surgery. It will also evaluate the effects of tVNS on recovery quality, autonomic function, and treatment safety. The main questions it aims to answer are:

Does transauricular vagus nerve stimulation reduce postoperative opioid consumption during the first 24 hours after surgery? Do different stimulation frequencies (high-frequency and low-frequency tVNS) produce different effects on postoperative pain and autonomic responses? Is transauricular vagus nerve stimulation safe and well tolerated in surgical patients?

Researchers will compare high-frequency tVNS, low-frequency tVNS, and sham stimulation (inactive stimulation) to determine their effects on postoperative pain and opioid requirements.

Participants will:

Be randomly assigned to receive high-frequency tVNS, low-frequency tVNS, or sham stimulation.

Receive two 30-minute stimulation sessions, one before anesthesia and one after surgery in the post-anesthesia care unit.

Undergo assessments of postoperative pain, opioid consumption, need for rescue analgesics, postoperative nausea and vomiting, heart rate changes, and quality of recovery.

Be monitored for adverse events related to the intervention during the study period.

A total of 174 participants will be enrolled in this single-center, randomized, double-blind, sham-controlled clinical trial.

Read the detailed description

Postoperative pain remains a major challenge in perioperative care and is associated with delayed recovery, increased healthcare utilization, and greater opioid consumption. Despite advances in multimodal analgesia, opioid medications continue to play a central role in postoperative pain management and may be associated with adverse effects such as nausea, vomiting, respiratory depression, and prolonged recovery. Therefore, the development of effective non-pharmacological adjunctive strategies is of considerable clinical interest.

Transauricular vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve through the external ear. Experimental and clinical studies suggest that vagal stimulation may modulate pain perception through activation of central autonomic pathways, enhancement of descending inhibitory pain mechanisms, and regulation of inflammatory responses. Previous clinical trials have demonstrated promising effects of tVNS on acute and chronic pain conditions, including reductions in postoperative pain scores.

However, the optimal stimulation parameters for perioperative analgesia remain uncertain. In particular, the influence of stimulation frequency on clinical outcomes and autonomic responses has not been adequately investigated. Different stimulation frequencies may activate distinct neural pathways and produce different effects on pain modulation and autonomic regulation.

This study is designed to evaluate the effects of different frequencies of transauricular vagus nerve stimulation applied before and after surgery in adult patients undergoing elective surgical procedures. In addition to assessing postoperative opioid requirements, the study will explore the relationship between autonomic responses and postoperative recovery. The findings may contribute to the optimization of non-pharmacological analgesic strategies and support the incorporation of transauricular vagus nerve stimulation into multimodal perioperative pain management protocols.

03

Conditions studied

  • Postoperative Pain
  • Postoperative Nausea and Vomiting (PONV)
  • Opioid Consumption, Postoperative

Keywords

  • Postoperative Pain
  • Transauricular Vagus Nerve Stimulation
  • tVNS
  • Neuromodulation
  • Opioid Consumption
  • Pain Management
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 59 years.
  • Undergoing elective abdominal or urologic surgery.
  • (ASA) physical status I-III.
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of neurological disorders.
  • History of psychiatric disorders.
  • Inability to understand study procedures.
  • Pregnancy.
  • Cognitive impairment.
  • Communication difficulties that interfere with study assessments.
  • Auricular dermatitis or skin lesions at the stimulation site.
  • Pre-existing cardiac arrhythmia.
  • Chronic opioid use.
  • Implanted electronic medical devices, including pacemakers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    High-Frequency tVNS

    Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 60-120 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.

    Device: Transauricular Vagus Nerve Stimulation (tVNS)

  • Experimental
    Low-Frequency tVNS

    Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 10-20 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.

    Device: Transauricular Vagus Nerve Stimulation (tVNS)

  • Sham comparator
    Sham tVNS

    Participants will receive sham transauricular vagus nerve stimulation. The device will be positioned and activated to mimic active treatment, but stimulation will be discontinued shortly after initiation. Participants will undergo two 30-minute sessions, one before anesthesia and one after surgery, while maintaining blinding to treatment allocation.

    Device: Sham Transauricular Vagus Nerve Stimulation (sham tVNS)

Interventions

  • DeviceTransauricular Vagus Nerve Stimulation (tVNS)

    Non-invasive electrical stimulation of the auricular branch of the vagus nerve applied bilaterally through ear electrodes. Stimulation is delivered before anesthesia and after surgery using predefined frequency settings.

  • DeviceSham Transauricular Vagus Nerve Stimulation (sham tVNS)

    Sham stimulation delivered using the same device and electrode placement as active stimulation. The device is activated to mimic treatment but does not deliver therapeutic electrical stimulation.

06

What researchers measure

Primary outcomes

  1. Total postoperative opioid consumption during the first 24 hours after surgery

    Total opioid consumption during the first 24 postoperative hours, recorded according to the institutional postoperative analgesia protocol.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Postoperative pain intensity (VAS)

    Pain intensity measured using a 100-mm Visual Analog Scale (VAS). Pain scores will be assessed at predefined postoperative time points and compared among study groups.

    Time frame: Before stimulation in the post-anesthesia care unit, immediately after stimulation, 2 hours after surgery, and 24 hours after surgery

  2. Rescue analgesic use

    Number of participants requiring rescue analgesics and total rescue analgesic administration during the first 24 postoperative hours.

    Time frame: Within 24 hours after surgery

  3. Postoperative nausea and vomiting (PONV)

    Incidence of postoperative nausea and/or vomiting and use of rescue antiemetic medication during the postoperative period.

    Time frame: Within 24 hours after surgery

  4. Heart rate changes

    Changes in heart rate measured immediately before and immediately after transauricular vagus nerve stimulation sessions as an indicator of autonomic nervous system activity.

    Time frame: Immediately before and immediately after each stimulation session (preoperative and postoperative).

  5. Quality of Recovery (QoR-15 Score)

    Quality of postoperative recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15). Higher scores indicate better recovery.

    Time frame: Baseline (preoperative) and 24 hours after surgery.

  6. Adverse events related to transauricular Vagus Nerve Stimulation

    Incidence of adverse events potentially related to the intervention, including auricular discomfort, skin irritation, headache, bradycardia, hypotension, bronchospasm, or other treatment-related events.

    Time frame: From the first stimulation session until 24 hours after surgery.

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitário Professor Edgard Santos, Federal University of Bahia (HUPES-UFBA)
    Salvador, Estado de Bahia 40170-110, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications arising from this study will be made available, including demographic characteristics, intervention allocation, primary and secondary outcome measures, and adverse event data. Data will be shared only after removal of all direct identifiers to protect participant confidentiality.

Time frame: De-identified individual participant data and supporting study documents will be available beginning 3 months after publication of the primary study results and will remain available indefinitely, with no end date.

Access criteria: De-identified data will be available to qualified researchers who provide a methodologically sound research proposal. Requests should be submitted to the principal investigator. Access will be granted following review and approval of the proposed use and execution of a data-sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Nov 2026, 5 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 4, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07633444
Lead sponsor
Federal University of Bahia
Collaborators
Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil
Responsible party
Joao Paulo Aureliano de Carvalho (Researcher, Department of Anesthesiology and Surgery, Federal University of Bahia) — Principal investigator
First posted
Jun 8, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 4, 2026 (estimated)
Last update
Jun 10, 2026

Study contacts

Rodrigo L Alves, MD, PhD
Contact
rlalves@ufba.br
71 99961-9818
João Paulo A de Carvalho
Contact
joaoaureliano@ufba.br
75 98295-3834
Rodrigo M Vieira, MD
principal investigator · Botucatu Medical School, São Paulo State University (UNESP)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion